PL3867244T3 - Pochodne 4-pirazyn-2-ylometylomorfoliny i ich zastosowanie jako lek - Google Patents

Pochodne 4-pirazyn-2-ylometylomorfoliny i ich zastosowanie jako lek

Info

Publication number
PL3867244T3
PL3867244T3 PL19786343.4T PL19786343T PL3867244T3 PL 3867244 T3 PL3867244 T3 PL 3867244T3 PL 19786343 T PL19786343 T PL 19786343T PL 3867244 T3 PL3867244 T3 PL 3867244T3
Authority
PL
Poland
Prior art keywords
ylmethylmorpholine
pyrazin
medicine
derivatives
ylmethylmorpholine derivatives
Prior art date
Application number
PL19786343.4T
Other languages
English (en)
Inventor
Riccardo Giovannini
Angelo Ceci
Cornelia Dorner-Ciossek
Roland Pfau
Dieter Wiedenmayer
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of PL3867244T3 publication Critical patent/PL3867244T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL19786343.4T 2018-10-17 2019-10-16 Pochodne 4-pirazyn-2-ylometylomorfoliny i ich zastosowanie jako lek PL3867244T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18200943 2018-10-17
PCT/EP2019/078027 WO2020079039A1 (en) 2018-10-17 2019-10-16 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament

Publications (1)

Publication Number Publication Date
PL3867244T3 true PL3867244T3 (pl) 2023-05-22

Family

ID=63878518

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19786343.4T PL3867244T3 (pl) 2018-10-17 2019-10-16 Pochodne 4-pirazyn-2-ylometylomorfoliny i ich zastosowanie jako lek

Country Status (38)

Country Link
US (3) US11166958B2 (pl)
EP (1) EP3867244B1 (pl)
JP (1) JP7093468B2 (pl)
KR (1) KR102840105B1 (pl)
CN (1) CN112888685B (pl)
AR (1) AR116711A1 (pl)
AU (1) AU2019362330B2 (pl)
BR (1) BR112021004993A2 (pl)
CA (1) CA3113308A1 (pl)
CL (1) CL2021000858A1 (pl)
CO (1) CO2021004612A2 (pl)
CR (1) CR20210184A (pl)
DK (1) DK3867244T3 (pl)
DO (1) DOP2021000069A (pl)
EA (1) EA202191014A1 (pl)
EC (1) ECSP21027009A (pl)
ES (1) ES2940184T3 (pl)
FI (1) FI3867244T3 (pl)
HR (1) HRP20230249T1 (pl)
HU (1) HUE061891T2 (pl)
IL (1) IL282142B2 (pl)
JO (1) JOP20210075B1 (pl)
LT (1) LT3867244T (pl)
MA (1) MA53898B1 (pl)
MX (1) MX2021004418A (pl)
MY (1) MY205127A (pl)
NZ (1) NZ773672A (pl)
PE (1) PE20211278A1 (pl)
PH (1) PH12021550834A1 (pl)
PL (1) PL3867244T3 (pl)
PT (1) PT3867244T (pl)
RS (1) RS63988B1 (pl)
SA (1) SA521421756B1 (pl)
SG (1) SG11202103806VA (pl)
SI (1) SI3867244T1 (pl)
TW (1) TWI828779B (pl)
UA (1) UA128408C2 (pl)
WO (1) WO2020079039A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11376258B2 (en) * 2019-06-04 2022-07-05 Boehringer Ingelheim International Gmbh Purine derivatives and the use thereof as medicament
WO2025233259A1 (en) 2024-05-07 2025-11-13 Boehringer Ingelheim International Gmbh Compound for use in the treatment of depression, obsessive-compulsive disorder, post-traumatic stress disorder and/or borderline personality disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
CA2453383C (en) * 2001-07-24 2010-04-06 Richter Gedeon Vegyeszeti Gyar Rt Piperidine derivatives as nmda receptor antagonists
AU2006322067A1 (en) * 2005-12-06 2007-06-14 Merck Sharp & Dohme Corp. Morpholine carboxamide prokineticin receptor antagonists
US20110319416A1 (en) * 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
WO2012128582A2 (en) 2011-03-23 2012-09-27 Hyundai Pharm Co., Ltd. A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
WO2014060398A1 (en) * 2012-10-18 2014-04-24 F. Hoffmann-La Roche Ag Ethynyl derivatives as modulators of mglur5 receptor activity
CA2936886A1 (en) * 2014-02-27 2015-08-03 Merck Patent Gmbh Heterocyclic compounds as nav channel inhibitors and uses thereof
US10913736B2 (en) 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
BR112018007181A2 (pt) * 2015-10-14 2018-10-16 Bristol-Myers Squibb Company antagonistas de nr2b seletivos

Also Published As

Publication number Publication date
EP3867244A1 (en) 2021-08-25
KR102840105B1 (ko) 2025-07-31
CA3113308A1 (en) 2020-04-23
SG11202103806VA (en) 2021-05-28
CN112888685B (zh) 2023-09-22
US20210393644A1 (en) 2021-12-23
IL282142B1 (en) 2023-12-01
WO2020079039A1 (en) 2020-04-23
ES2940184T3 (es) 2023-05-04
DK3867244T3 (da) 2023-05-01
JP7093468B2 (ja) 2022-06-29
MX2021004418A (es) 2021-07-06
JOP20210075B1 (ar) 2024-12-22
DOP2021000069A (es) 2021-05-31
PT3867244T (pt) 2023-02-22
MA53898A (fr) 2022-01-26
AR116711A1 (es) 2021-06-02
CN112888685A (zh) 2021-06-01
US20200121691A1 (en) 2020-04-23
RS63988B1 (sr) 2023-03-31
MY205127A (en) 2024-10-03
IL282142A (en) 2021-05-31
AU2019362330B2 (en) 2024-03-28
EP3867244B1 (en) 2023-01-18
PH12021550834A1 (en) 2021-10-04
IL282142B2 (en) 2024-04-01
HRP20230249T1 (hr) 2023-04-14
JOP20210075A1 (ar) 2023-01-30
MA53898B1 (fr) 2023-03-31
AU2019362330A1 (en) 2021-04-08
SI3867244T1 (sl) 2023-04-28
TW202031262A (zh) 2020-09-01
CL2021000858A1 (es) 2021-10-01
TWI828779B (zh) 2024-01-11
NZ773672A (en) 2024-12-20
US20250345341A1 (en) 2025-11-13
CR20210184A (es) 2021-05-26
ECSP21027009A (es) 2021-05-31
HUE061891T2 (hu) 2023-09-28
BR112021004993A2 (pt) 2021-06-08
US11166958B2 (en) 2021-11-09
JP2022505080A (ja) 2022-01-14
SA521421756B1 (ar) 2023-02-12
UA128408C2 (uk) 2024-07-03
KR20210079325A (ko) 2021-06-29
CO2021004612A2 (es) 2021-04-30
PE20211278A1 (es) 2021-07-19
EA202191014A1 (ru) 2021-11-09
FI3867244T3 (fi) 2023-03-20
LT3867244T (lt) 2023-03-10

Similar Documents

Publication Publication Date Title
IL283197A (en) Microbiocidal 2-acylamino-thiazole-4-carboxamide derivatives
HUE058687T2 (hu) Azonnali elõkészítés
IL283492A (en) Etching compositions
LT3830085T (lt) Deuterinti lanifibranoro dariniai
DK3870234T3 (da) Antistoflægemiddelkonjugater omfattende ecteinascidinderivater
EP4013751C0 (en) 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES
EP3856268C0 (en) SELF-LUBRICATING MEDICAL SUPPLIES
DK3768669T3 (da) Piperazinazaspiroderivater
EP3565502A4 (en) Oral irrigator
EP3781576C0 (en) BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES
EP4077334C0 (en) FUROINDAZOLE DERIVATIVES
EP4021904C0 (en) ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES
EP3898217C0 (en) PAPER TISSUE PRODUCT
EP3856755A4 (en) Terpinoid derivatives and uses thereof
IL282157A (en) Compounds and therapeutic uses thereof
DK3796975T3 (da) Sulfonylaminobenzamidderivater
DK3823971T3 (da) Substituerede triazol-quinoxalin-derivater
IL282343A (en) Aqueous pharmaceutical formulations
PL3867244T3 (pl) Pochodne 4-pirazyn-2-ylometylomorfoliny i ich zastosowanie jako lek
DK3894410T3 (da) Substituerede xanthinderivater
DK3863580T3 (da) Engangsble
DK3770162T3 (da) Dihydrochromenderivater
EP3639800A4 (en) PULL-ON DISPOSABLE DIAPER
EP3590513A4 (en) DRUG
IL280118A (en) Medicinal preparation for external use